Liposome encapsulated daunorubicin (daunoxome) for acute leukemia

A. Ermacora, M. Michieli, F. Pea, G. Visani, A. Bucalossi, D. Russo

Research output: Contribution to journalArticle


Daunoxome (DNX, Nexstar) was given, as a single agent, to 11 patients with very poor-risk acute leukemia. Pharmacokinetic data were also obtained from 9 of the 11 cases. This small pilot study show that the toxic profile of this liposomal-encapsulated anthracycline is low.

Original languageEnglish
Pages (from-to)324-325
Number of pages2
Issue number3
Publication statusPublished - 2000


  • Acute leukemia
  • Daunorubicin
  • Liposome

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Liposome encapsulated daunorubicin (daunoxome) for acute leukemia'. Together they form a unique fingerprint.

  • Cite this

    Ermacora, A., Michieli, M., Pea, F., Visani, G., Bucalossi, A., & Russo, D. (2000). Liposome encapsulated daunorubicin (daunoxome) for acute leukemia. Haematologica, 85(3), 324-325.